Switch to:
Also traded in: Germany, Japan

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
MNOV's Cash to Debt is ranked higher than
91% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 42.60 vs. MNOV: No Debt )
Ranked among companies with meaningful Cash to Debt only.
MNOV' s Cash to Debt Range Over the Past 10 Years
Min: 0.67  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
MNOV's Interest Coverage is ranked higher than
87% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. MNOV: No Debt )
Ranked among companies with meaningful Interest Coverage only.
MNOV' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: 14.68
M-Score: -3.84
WACC vs ROIC
1.06%
-98.69%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -33.34
MNOV's ROE (%) is ranked lower than
51% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: -31.92 vs. MNOV: -33.34 )
Ranked among companies with meaningful ROE (%) only.
MNOV' s ROE (%) Range Over the Past 10 Years
Min: -73.58  Med: -42.52 Max: -19.99
Current: -33.34
-73.58
-19.99
ROA (%) -28.99
MNOV's ROA (%) is ranked lower than
51% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. MNOV: -28.99 )
Ranked among companies with meaningful ROA (%) only.
MNOV' s ROA (%) Range Over the Past 10 Years
Min: -52.77  Med: -30.28 Max: -16.41
Current: -28.99
-52.77
-16.41
ROC (Joel Greenblatt) (%) -31262.86
MNOV's ROC (Joel Greenblatt) (%) is ranked lower than
94% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -387.57 vs. MNOV: -31262.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MNOV' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -31262.86  Med: -4249.79 Max: -109.01
Current: -31262.86
-31262.86
-109.01
Revenue Growth (3Y)(%) -100.00
MNOV's Revenue Growth (3Y)(%) is ranked lower than
97% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 3.70 vs. MNOV: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MNOV' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0 Max: -100
Current: -100
EBITDA Growth (3Y)(%) -20.40
MNOV's EBITDA Growth (3Y)(%) is ranked lower than
72% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. MNOV: -20.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MNOV' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -83.3  Med: -27.9 Max: 188.9
Current: -20.4
-83.3
188.9
EPS Growth (3Y)(%) -20.60
MNOV's EPS Growth (3Y)(%) is ranked lower than
69% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. MNOV: -20.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MNOV' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -86.2  Med: -26.85 Max: 254
Current: -20.6
-86.2
254
» MNOV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

MNOV Guru Trades in Q3 2015

Jim Simons 103,100 sh (-10.89%)
» More
Q4 2015

MNOV Guru Trades in Q4 2015

Jim Simons 98,200 sh (-4.75%)
» More
Q1 2016

MNOV Guru Trades in Q1 2016

Jim Simons 100,100 sh (+1.93%)
» More
Q2 2016

MNOV Guru Trades in Q2 2016

Jim Simons 34,500 sh (-65.53%)
» More
» Details

Insider Trades

Latest Guru Trades with MNOV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:AMEX:MDGN, NAS:QURE, NAS:CRIS, NAS:CMRX, NAS:ABUS, NAS:VTAE, NAS:ARGS, NAS:CNCE, NAS:FLKS, NAS:CBMG, OTCPK:MVRBF, NAS:OVAS, NAS:NVIV, NAS:CYNA, NAS:IDRA, OTCPK:BNOEY, OTCPK:SPHRY, NAS:EGLT, NAS:RDHL, NAS:CRBP » details
Traded in other countries:RMN.Germany, 4875.Japan,
MediciNova Inc is a biopharmaceutical company. It is engaged in acquiring and developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs.

MediciNova Inc was incorporated in the State of Delaware in September 2000.It is a biopharmaceutical company focused on developing novel, small molecule therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the U.S. market. The Company operates in a single operating segment - the acquisition and development of small molecule therapeutics for the treatment of serious diseases with unmet medical needs. The Company currently focuses its development activities on MN-166 (ibudilast) for neurological disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and substance dependence (e.g.,methamphetamine dependence, opioid dependence, and alcohol dependence), and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). Its pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.

Ratios

vs
industry
vs
history
P/B 5.62
MNOV's P/B is ranked lower than
67% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: 3.67 vs. MNOV: 5.62 )
Ranked among companies with meaningful P/B only.
MNOV' s P/B Range Over the Past 10 Years
Min: 0.18  Med: 1.18 Max: 9.45
Current: 5.62
0.18
9.45
Current Ratio 20.42
MNOV's Current Ratio is ranked higher than
92% of the 918 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. MNOV: 20.42 )
Ranked among companies with meaningful Current Ratio only.
MNOV' s Current Ratio Range Over the Past 10 Years
Min: 1.31  Med: 10.14 Max: 49.29
Current: 20.42
1.31
49.29
Quick Ratio 20.42
MNOV's Quick Ratio is ranked higher than
92% of the 918 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. MNOV: 20.42 )
Ranked among companies with meaningful Quick Ratio only.
MNOV' s Quick Ratio Range Over the Past 10 Years
Min: 1.31  Med: 10.14 Max: 49.29
Current: 20.42
1.31
49.29

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -19.90
MNOV's 3-Year Average Share Buyback Ratio is ranked lower than
67% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: -11.50 vs. MNOV: -19.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MNOV' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -520.6  Med: -13.9 Max: 0
Current: -19.9
-520.6
0

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.65
MNOV's Price/Net Cash is ranked lower than
65% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 5.78 vs. MNOV: 9.65 )
Ranked among companies with meaningful Price/Net Cash only.
MNOV' s Price/Net Cash Range Over the Past 10 Years
Min: 0.71  Med: 5.49 Max: 30.33
Current: 9.65
0.71
30.33
Price/Net Current Asset Value 9.50
MNOV's Price/Net Current Asset Value is ranked lower than
68% of the 618 Companies
in the Global Biotechnology industry.

( Industry Median: 5.45 vs. MNOV: 9.50 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MNOV' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.69  Med: 4.52 Max: 20.79
Current: 9.5
0.69
20.79
Price/Tangible Book 9.07
MNOV's Price/Tangible Book is ranked lower than
74% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: 4.38 vs. MNOV: 9.07 )
Ranked among companies with meaningful Price/Tangible Book only.
MNOV' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.4  Med: 3.68 Max: 60.74
Current: 9.07
0.4
60.74
Price/Projected FCF 50.67
MNOV's Price/Projected FCF is ranked lower than
93% of the 168 Companies
in the Global Biotechnology industry.

( Industry Median: 3.36 vs. MNOV: 50.67 )
Ranked among companies with meaningful Price/Projected FCF only.
MNOV' s Price/Projected FCF Range Over the Past 10 Years
Min: 29.36  Med: 46.14 Max: 62.92
Current: 50.67
29.36
62.92
Earnings Yield (Greenblatt) (%) -6.01
MNOV's Earnings Yield (Greenblatt) (%) is ranked higher than
57% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.90 vs. MNOV: -6.01 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MNOV' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -6.19  Med: 99.2 Max: 8448.3
Current: -6.01
-6.19
8448.3

More Statistics

EPS (TTM) $ -0.36
Beta-0.07
Short Percentage of Float12.67%
52-Week Range $2.62 - 10.16
Shares Outstanding (Mil)34.47
» More Articles for MNOV

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
MEDICINOVA INC Financials Jul 30 2016
MNOV: Interim Analysis For Phase 2b Trial of MN-166 in Progressive MS in 4Q16 Jul 29 2016
MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure Jul 27 2016
MEDICINOVA INC Files SEC form 10-Q, Quarterly Report Jul 26 2016
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment... Jul 24 2016
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment... Jul 24 2016
MediciNova Announces Initiation of Interim Efficacy Analysis in Phase 2b Trial of MN-166 (ibudilast)... Jul 13 2016
MediciNova Announces Initiation of Interim Efficacy Analysis in Phase 2b Trial of MN-166 (ibudilast)... Jul 13 2016
MediciNova Announces Results from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence... Jun 29 2016
MediciNova Announces Results from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence... Jun 29 2016
MediciNova Added to Russell 3000® Index and Russell Global Index Jun 26 2016
MediciNova Added to Russell 3000® Index and Russell Global Index Jun 26 2016
MEDICINOVA INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 13 2016
MediciNova, Inc. :MNOV-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 Jun 06 2016
MediciNova Announces Additional Results from the Completed Trial of MN-166 (ibudilast) in Alcohol... May 25 2016
MNOV: Positive Trends Seen in Preliminary Data Presented on MN-166 in ALS Apr 29 2016
MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure Apr 28 2016
MEDICINOVA INC Files SEC form 10-Q, Quarterly Report Apr 27 2016
MediciNova Announces Interim Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the... Apr 20 2016
MediciNova, Inc. (NASDAQ: MNOV) - Analyst Coverage Initiated; Report by Broad Street Apr 04 2016
MediciNova Gains 6% Following Positive Mention In Medical Journal Mar 31 2016
MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors... Mar 31 2016
MediciNova Announces Publication of Positive Findings from Completed Phase 1b Clinical Trial of... Mar 30 2016
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 in China Mar 27 2016
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment... Mar 23 2016
FDA Grants Fast Track Designation for MediciNova's MN-166 (ibudilast) for Progressive Multiple... Mar 22 2016
LifeSci Capital Initiates Coverage of MediciNova Mar 14 2016
Biotech Trade Report Mar 14 2016
MNOV: Multiple Catalysts Ahead in 2016 Mar 09 2016
MediciNova, Inc. (NASDAQ: MNOV) Ongoing Clinical Trial of MN-166 Mar 01 2016
3 Stocks That Should be in Your Portfolio Today Feb 26 2016
MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure Feb 26 2016
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment... Jan 27 2016
FDA Grants Rare Pediatric Disease Designation to MediciNova’s MN-166 (ibudilast) for the Treatment... Jan 18 2016
MediciNova Receives Notice of Allowance for New Patent Covering MN-029 (denibulin) di-hydrochloride... Jan 13 2016
FDA Grants Fast Track Designation for MediciNova's MN-166 (ibudilast) for the Treatment of... Dec 16 2015
MediciNova Receives Notice of Allowance for New Patent Covering MN-029 (denibulin) di-hydrochloride... Dec 14 2015
MediciNova Announces Positive Interim Safety and Clinical Outcomes Data From Clinical Trial of... Dec 13 2015
MediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use... Dec 09 2015
MediciNova Announces Presentation Regarding Clinical Trial of MN-166 (ibudilast) in ALS at the 6th... Dec 06 2015
MediciNova Receives Notice of Allowance for New Patent Covering MN-221 (bedoradrine) for the... Nov 10 2015
MediciNova Announces Interim Data From Clinical Trial of MN-166 (ibudilast) in ALS to be Presented... Nov 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)